Close
0
You have no items in your order cart.
Search
Filters

Purevax Felv - 1ml x10

Feline leukaemia virus (FeLV) is contagious, lethal and incurable. FeLV can lead to the development of cancer in up to 30% of persistently infected cats and can suppress the immune system and bone marrow function, resulting in additional infectious diseases or anaemia. PUREVAX Recombinant FeLV vaccine: • Is the only non-adjuvanted feline leukaemia vaccine • Uses advanced recombinant canarypox-vectored vaccine technology • Comprehensive immune response PUREVAX Recombinant FelV contains a non-adjuvant lyophilized suspension of a recombinant vectored feline leukaemia vaccine plus sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to feline leukaemia. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats. Indications PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks of age or older as an aid in the prevention of disease due to feline leukaemia virus. Dosage Aseptically rehydrate the lyophilized vaccine with 1 ml of the accompanying sterile water diluent. and agitate. Administer 1 ml (1 dose) subcutaneously. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual revaccination is recommended. Diagnostic testing for FelV prior to vaccination is recommend

This is a restricted product.
Please visit your Favourites List in My Account to purchase this item.

Availability: In stock
SKU: 104151
Customers who bought this item also bought

Nobi-Vac Kc. - 1ml x5

121660
A live vaccine against canine infectious tracheobronchitis caused by B. bronchiseptica and parainfluenza virus in dogs. Infectious tracheobronchitis is a highly contagious, multi-factorial disease of the dog’s respiratory tract. Bordetella bronchiseptica and canine parainfluenza are the most common bacterial and viral agents associated with the disease. Environmental factors such as stress, ventilation and climate may also contribute. Nobivac KC is a low volume dose (0.4ml), easy to administer, intranasal vaccine which acts against both the key causative agents of infectious tracheobronchitis and provides protection within 72 hours and lasts for at least 12 months. It can be used in puppies as young as three weeks and in pregnant bitches.

Eurican Dhppi - 1ml x10

124090
A combined live freeze-dried vaccine against canine distemper, infectious canine hepatitis, canine parvovirus and canine parainfluenza virus type 2. Each 1-ml dose of vaccine contains attenuated canine distemper virus, at least 104.0 CCID50, attenuated canine adenovirus (CAV2), at least 102.5 CCID50, attenuated canine parvovirus, at least 104.9 CCID50, attenuated canine parainfluenza type 2 virus, at least 104.7 CCID50 Uses Dogs and puppies from 8 weeks of age: Active immunization against distemper to reduce mortality and clinical signs; against infectious canine hepatitis to prevent clinical signs; against parvovirus to prevent clinical signs and reduce mortality and viral excretion; and against parainfluenza type 2 infections to reduce clinical signs and viral excretion. Onset of immunity: 2 weeks after completion of the primary vaccination course. Duration of immunity: 1 year. Dosage and administration Reconstitute the vaccine with Eurican L using a clean sterile syringe. Use the vaccine immediately after reconstitution of the freeze-dried pellet. Apply usual aseptic procedures. Use sterile and/or disinfectant-free equipment for injection purposes. Administer by subcutaneous injection. The following vaccination schedule is recommended: Primary vaccination: 1st injection: from 8th week of age. 2nd injection: 3 to 5 weeks later, from 12th week of age. Revaccination: Booster injections should be given annually thereafter.

Eurican L Multi - 1ml x10

141334
Indications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not establishedIndications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not established

Vetoryl - 60mg - 31 pack

104871
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs. Active ingredient: Trilostane